Organogenesis (NASDAQ:ORGO) Issues Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• Organogenesis reported earnings of ($0.09) EPS for the quarter, missing analyst expectations by ($0.08), with revenues of $101.01 million versus estimates of $104.75 million.
• Despite the earnings miss, Cantor Fitzgerald increased its price target for Organogenesis from $7.00 to $9.00 and rated the stock "overweight."
• Insider Lori Freedman purchased 9,022 shares at $2.99 each, increasing her total holdings in the company by 1.08%.

Organogenesis (NASDAQ:ORGO - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08), Zacks reports. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.36%. The company had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis updated its FY 2025 guidance to EPS.

Organogenesis Trading Up 0.7%

ORGO traded up $0.03 on Friday, hitting $4.55. 1,386,400 shares of the company's stock were exchanged, compared to its average volume of 846,873. Organogenesis has a fifty-two week low of $2.28 and a fifty-two week high of $6.71. The firm has a 50-day moving average price of $3.98 and a 200-day moving average price of $4.06. The stock has a market cap of $577.17 million, a price-to-earnings ratio of -32.50 and a beta of 1.76.

Analyst Ratings Changes

ORGO has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their price target on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research note on Friday. BTIG Research reissued a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th.

Insider Transactions at Organogenesis

In other Organogenesis news, insider Lori Freedman bought 9,022 shares of the stock in a transaction on Friday, June 6th. The shares were bought at an average price of $2.99 per share, with a total value of $26,975.78. Following the purchase, the insider directly owned 846,459 shares in the company, valued at $2,530,912.41. This trade represents a 1.08% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have acquired 252,264 shares of company stock worth $725,732. Insiders own 33.00% of the company's stock.

Institutional Investors Weigh In On Organogenesis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in shares of Organogenesis during the 1st quarter worth $105,000. Creative Planning raised its holdings in shares of Organogenesis by 84.5% during the 2nd quarter. Creative Planning now owns 35,392 shares of the company's stock worth $130,000 after acquiring an additional 16,205 shares during the period. Finally, Cetera Investment Advisers purchased a new position in shares of Organogenesis during the 2nd quarter worth $222,000. Institutional investors and hedge funds own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.